Anti-Human CD79B Reference Antibody (Iladatuzumab, RUO) (HW431026)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW431026
Description	Iladatuzumab (HW431026) is a research-grade recombinant antibody targeting CD79B. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P40259
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	DCDS0780A, MCDS0593A, RO7032005, 1906205-76-2
Background	B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy).
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects CD79β/CD79B in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Iladatuzumab
Western blot

Western blot analysis was performed using anti-CD79β/CD79B monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human CD79β/CD79B (Catalog No: HW431011)
Flow cytometry

Flow-cytometry using APC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.
Flow cytometry

Flow-cytometry using PE anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.
Flow cytometry

Flow-cytometry using FITC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.